Baseline and clinical characteristics of patients evaluable for responses
| . | Primary refractory (N = 73), n (%) . | Primary responsive (N = 1013), n (%) . | Total (N = 1086), n (%) . | P value . |
|---|---|---|---|---|
| Age (y) | .50 | |||
| Median (range) | 63.5 (27.1-85.4) | 62.5 (23.9-90.4) | 62.6 (23.9-90.4) | |
| Race | .34 | |||
| White | 67 (91.8) | 941 (94.0) | 1008 (93.9) | |
| Black | 2 (2.7) | 26 (2.6) | 28 (2.6) | |
| Asian | 3 (4.1) | 14 (1.4) | 17 (1.6) | |
| Other | 1 (1.4) | 20 (2.0) | 21 (2.0) | |
| Sex | .12 | |||
| Female | 34 (46.6) | 380 (37.5) | 414 (38.1) | |
| Male | 39 (53.4) | 633 (62.5) | 672 (61.9) | |
| ECOG | .31 | |||
| 0 | 17 (37.0) | 406 (49.8) | 423 (49.1) | |
| 1 | 20 (43.5) | 320 (39.2) | 340 (39.4) | |
| 2 | 7 (15.2) | 73 (8.9) | 80 (9.3) | |
| 3 | 2 (4.3) | 16 (2.0) | 18 (2.1) | |
| 4 | 0 (0.0) | 1 (0.1) | 1 (0.1) | |
| ISS | .09 | |||
| 1 | 17 (28.3) | 354 (38.1) | 371 (37.6) | |
| 2 | 20 (33.3) | 335 (36.1) | 355 (35.9) | |
| 3 | 23 (38.3) | 239 (25.8) | 262 (26.5) | |
| R-ISS | <.01 | |||
| 1 | 12 (22.6) | 228 (26.1) | 240 (25.9) | |
| 2 | 26 (49.1) | 528 (60.6) | 554 (59.9) | |
| 3 | 15 (28.3) | 116 (13.3) | 131 (14.2) | |
| R2-ISS | .01 | |||
| Low | 7 (17.9) | 175 (24.1) | 182 (23.8) | |
| Low-intermediate | 6 (15.4) | 255 (35.2) | 261 (34.2) | |
| High-intermediate | 24 (61.5) | 264 (36.4) | 288 (37.7) | |
| High | 2 (5.1) | 31 (4.3) | 33 (4.3) | |
| mSMART | <.01 | |||
| Low-risk | 21 (38.2) | 502 (57.1) | 523 (56.0) | |
| High-risk | 34 (61.8) | 377 (42.9) | 411 (44.0) | |
| FISH | .05 | |||
| Standard-Risk | 27 (40.9) | 516 (55.4) | 543 (54.4) | |
| High-Risk | 27 (40.9) | 314 (33.7) | 341 (34.2) | |
| Double-Hit | 12 (18.2) | 102 (10.9) | 114 (11.4) | |
| LDH | .31 | |||
| Increased | 14 (29.8) | 186 (23.2) | 200 (23.6) | |
| Normal | 33 (70.2) | 614 (76.8) | 647 (76.4) | |
| GFR (mL/min per 1.73 m2) | <.01 | |||
| <30 | 9 (14.3) | 162 (16.9) | 171 (16.8) | |
| 30-60 | 29 (46.0) | 262 (27.4) | 291 (28.5) | |
| >60 | 25 (39.7) | 533 (55.7) | 558 (54.7) | |
| Induction regimen | .28 | |||
| VRD | 66 (90.4) | 828 (81.7) | 894 (82.3) | |
| KRD | 4 (5.5) | 87 (8.6) | 91 (8.4) | |
| Quadruplet | 2 (2.7) | 79 (7.8) | 81 (7.5) | |
| Other | 1 (1.4) | 19 (1.9) | 20 (1.8) | |
| Upfront ASCT | <.01 | |||
| No | 69 (94.5) | 349 (34.8) | 418 (38.8) | |
| Yes | 4 (5.5) | 654 (65.2) | 658 (61.2) | |
| Heavy chain | .72 | |||
| IgA | 12 (24.0) | 190 (23.9) | 202 (23.9) | |
| IgD | 0 (0.0) | 7 (0.9) | 7 (0.8) | |
| IgG | 37 (74.0) | 593 (74.5) | 630 (74.5) | |
| IgM | 1 (2.0) | 6 (0.8) | 7 (0.8) | |
| Light chain | .34 | |||
| κ | 40 (56.3) | 667 (66.6) | 707 (65.9) | |
| λ | 31 (43.7) | 333 (33.2) | 364 (33.9) | |
| Number of collection attempts | .31 | |||
| Median (range) | 2 (1-6) | 2 (1-7) | 2 (1-7) | |
| Collection yield (CD34+cells) | .63 | |||
| Median (range) | 9.8 (3.2-26.5) | 9.3 (2.4-33.1) | 9.3 (2.4-33.1) | |
| Clonal plasma cells in the BM | <.01 | |||
| Median (range) | 0.6 (0-1) | 0.5 (0-1) | 0.5 (0-1) |
| . | Primary refractory (N = 73), n (%) . | Primary responsive (N = 1013), n (%) . | Total (N = 1086), n (%) . | P value . |
|---|---|---|---|---|
| Age (y) | .50 | |||
| Median (range) | 63.5 (27.1-85.4) | 62.5 (23.9-90.4) | 62.6 (23.9-90.4) | |
| Race | .34 | |||
| White | 67 (91.8) | 941 (94.0) | 1008 (93.9) | |
| Black | 2 (2.7) | 26 (2.6) | 28 (2.6) | |
| Asian | 3 (4.1) | 14 (1.4) | 17 (1.6) | |
| Other | 1 (1.4) | 20 (2.0) | 21 (2.0) | |
| Sex | .12 | |||
| Female | 34 (46.6) | 380 (37.5) | 414 (38.1) | |
| Male | 39 (53.4) | 633 (62.5) | 672 (61.9) | |
| ECOG | .31 | |||
| 0 | 17 (37.0) | 406 (49.8) | 423 (49.1) | |
| 1 | 20 (43.5) | 320 (39.2) | 340 (39.4) | |
| 2 | 7 (15.2) | 73 (8.9) | 80 (9.3) | |
| 3 | 2 (4.3) | 16 (2.0) | 18 (2.1) | |
| 4 | 0 (0.0) | 1 (0.1) | 1 (0.1) | |
| ISS | .09 | |||
| 1 | 17 (28.3) | 354 (38.1) | 371 (37.6) | |
| 2 | 20 (33.3) | 335 (36.1) | 355 (35.9) | |
| 3 | 23 (38.3) | 239 (25.8) | 262 (26.5) | |
| R-ISS | <.01 | |||
| 1 | 12 (22.6) | 228 (26.1) | 240 (25.9) | |
| 2 | 26 (49.1) | 528 (60.6) | 554 (59.9) | |
| 3 | 15 (28.3) | 116 (13.3) | 131 (14.2) | |
| R2-ISS | .01 | |||
| Low | 7 (17.9) | 175 (24.1) | 182 (23.8) | |
| Low-intermediate | 6 (15.4) | 255 (35.2) | 261 (34.2) | |
| High-intermediate | 24 (61.5) | 264 (36.4) | 288 (37.7) | |
| High | 2 (5.1) | 31 (4.3) | 33 (4.3) | |
| mSMART | <.01 | |||
| Low-risk | 21 (38.2) | 502 (57.1) | 523 (56.0) | |
| High-risk | 34 (61.8) | 377 (42.9) | 411 (44.0) | |
| FISH | .05 | |||
| Standard-Risk | 27 (40.9) | 516 (55.4) | 543 (54.4) | |
| High-Risk | 27 (40.9) | 314 (33.7) | 341 (34.2) | |
| Double-Hit | 12 (18.2) | 102 (10.9) | 114 (11.4) | |
| LDH | .31 | |||
| Increased | 14 (29.8) | 186 (23.2) | 200 (23.6) | |
| Normal | 33 (70.2) | 614 (76.8) | 647 (76.4) | |
| GFR (mL/min per 1.73 m2) | <.01 | |||
| <30 | 9 (14.3) | 162 (16.9) | 171 (16.8) | |
| 30-60 | 29 (46.0) | 262 (27.4) | 291 (28.5) | |
| >60 | 25 (39.7) | 533 (55.7) | 558 (54.7) | |
| Induction regimen | .28 | |||
| VRD | 66 (90.4) | 828 (81.7) | 894 (82.3) | |
| KRD | 4 (5.5) | 87 (8.6) | 91 (8.4) | |
| Quadruplet | 2 (2.7) | 79 (7.8) | 81 (7.5) | |
| Other | 1 (1.4) | 19 (1.9) | 20 (1.8) | |
| Upfront ASCT | <.01 | |||
| No | 69 (94.5) | 349 (34.8) | 418 (38.8) | |
| Yes | 4 (5.5) | 654 (65.2) | 658 (61.2) | |
| Heavy chain | .72 | |||
| IgA | 12 (24.0) | 190 (23.9) | 202 (23.9) | |
| IgD | 0 (0.0) | 7 (0.9) | 7 (0.8) | |
| IgG | 37 (74.0) | 593 (74.5) | 630 (74.5) | |
| IgM | 1 (2.0) | 6 (0.8) | 7 (0.8) | |
| Light chain | .34 | |||
| κ | 40 (56.3) | 667 (66.6) | 707 (65.9) | |
| λ | 31 (43.7) | 333 (33.2) | 364 (33.9) | |
| Number of collection attempts | .31 | |||
| Median (range) | 2 (1-6) | 2 (1-7) | 2 (1-7) | |
| Collection yield (CD34+cells) | .63 | |||
| Median (range) | 9.8 (3.2-26.5) | 9.3 (2.4-33.1) | 9.3 (2.4-33.1) | |
| Clonal plasma cells in the BM | <.01 | |||
| Median (range) | 0.6 (0-1) | 0.5 (0-1) | 0.5 (0-1) |
ECOG, Eastern Cooperative Oncology Group; GFR, glomerular filtration rate; Ig, immunoglobulin; IMWG, International Myeloma Working Group; LDH, lactate dehydrogenase.